Healthcare Industry News: ICP monitor
News Release - September 11, 2007
Integra LifeSciences Announces Launch of the Camino Advanced Monitor, a State of the Art Monitoring System for Traumatic Brain Injury PatientsPLAINSBORO, N.J., Sept. 11, 2007 (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today the release of the Camino(R) Advanced Monitor (CAM), the latest addition to Integra's neuromonitoring product line.
Camino(R) Advanced Monitor is the newest offering in Integra's established line of Camino(R) ICP monitoring solutions. Integra designed the new monitor to incorporate numerous features requested by our clinicians, including an improved visual display screen, an optimized interface and an advanced ergonomic design. The Camino(R) Advanced Monitor accurately measures Intracranial Pressure (ICP) and Intracranial Temperature (ICT) via Integra's proven fiberoptic technology. The system also displays Mean Arterial Pressure (MAP) and Cerebral Perfusion Pressure (CPP), based on input from the patient bedside monitor.
Intracranial pressure monitoring is an essential component in the treatment of severe brain injury. The 2007 Guidelines for the Treatment of Traumatic Brain Injury, recently published by the Brain Trauma Foundation, contain specific recommendations with regard to monitoring intracranial pressure and brain tissue oxygen in severe Traumatic Brain Injury patients. The brain tissue oxygen level is monitored via Integra's Licox(R) Brain Tissue Oxygen Monitoring System. Both the Camino(R) Advanced Monitor and the Licox(R) Brain Tissue Oxygen Monitoring System may be easily connected to Integra's state of the art Mobius(TM) Multimodality Monitoring System via a built-in digital communication port. The Mobius(TM) system allows the clinician to monitor and record, at the bedside, multiple clinical measurements that are critical for the treatment of neurological injury.
Integra will be exhibiting the Camino(R) Advanced Monitor at the upcoming 2007 Congress of Neurological Surgeons Annual Meeting, which will take place in San Diego, CA on September 15 - 20.
The Integra NeuroSciences direct sales organization will sell the Camino(R) Advanced Monitor. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe involves more than 150 professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at http://www.integra-ls.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the use of the Camino(R) Advanced Monitor System, the Licox(R) Brain Tissue Oxygen Monitoring System and the Mobius(TM) Multimodality Monitoring System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the Risk Factors included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.